Safdarjung Hospital in India has become the country’s first public institution to offer CAR-T cell therapy, a groundbreaking treatment for cancer. This advanced immunotherapy harnesses a patient’s own genetically modified T cells to target and destroy cancer cells more effectively. Previously available only at private hospitals with high costs, the introduction of CAR-T cell therapy in a public institution makes this life-saving treatment more accessible to patients who may not have been able to afford it otherwise.
This development marks a significant milestone in India’s healthcare system, showcasing the government’s commitment to expanding cutting-edge cancer treatments. Experts believe that making CAR-T therapy available in public hospitals could lead to further advancements in cancer care and research. As more patients gain access to this innovative treatment, it has the potential to significantly improve survival rates and outcomes for individuals battling various forms of cancer. Click for More Details
